CL2023001901A1 - Inhibidor de señal de miostatina - Google Patents
Inhibidor de señal de miostatinaInfo
- Publication number
- CL2023001901A1 CL2023001901A1 CL2023001901A CL2023001901A CL2023001901A1 CL 2023001901 A1 CL2023001901 A1 CL 2023001901A1 CL 2023001901 A CL2023001901 A CL 2023001901A CL 2023001901 A CL2023001901 A CL 2023001901A CL 2023001901 A1 CL2023001901 A1 CL 2023001901A1
- Authority
- CL
- Chile
- Prior art keywords
- acvr2b
- signal inhibitor
- myostatin signal
- type
- skipping
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title 1
- 108010056852 Myostatin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102100027647 Activin receptor type-2B Human genes 0.000 abstract 3
- 101710191689 Activin receptor type-2B Proteins 0.000 abstract 3
- 101150031865 ACVR2B gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Compuesto capaz de permitir que una célula objetivo produzca un ARNm tipo 2B de receptor de activina mutante (ACVR2B) donde una parte de la secuencia que codifica algo o todo de la región intracelular de la ACVR2B de tipo natural está ausente, o una sal farmacéuticamente aceptable o hidrato de la misma, especificaciones de este, en particular un morfolino que dirige a la omisión de un exón seleccionado del rango 5-10 del gen ACVR2B, la composición farmacéutica que lo comprende y el uso terapéutico de estos productos para tratar una enfermedad amiotrófica en un individuo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1821269.6A GB201821269D0 (en) | 2018-12-28 | 2018-12-28 | Myostatin signal inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001901A1 true CL2023001901A1 (es) | 2023-12-15 |
Family
ID=65364695
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001712A CL2021001712A1 (es) | 2018-12-28 | 2021-06-25 | Inhibidor de señal de miostatina |
CL2023001902A CL2023001902A1 (es) | 2018-12-28 | 2023-06-27 | Inhibidor de señal de miostatina |
CL2023001901A CL2023001901A1 (es) | 2018-12-28 | 2023-06-27 | Inhibidor de señal de miostatina |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001712A CL2021001712A1 (es) | 2018-12-28 | 2021-06-25 | Inhibidor de señal de miostatina |
CL2023001902A CL2023001902A1 (es) | 2018-12-28 | 2023-06-27 | Inhibidor de señal de miostatina |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220119818A1 (es) |
EP (1) | EP3902916A1 (es) |
JP (1) | JP2022516207A (es) |
KR (1) | KR20210110593A (es) |
CN (1) | CN113272429A (es) |
AU (1) | AU2019415399A1 (es) |
BR (1) | BR112021012488A2 (es) |
CA (1) | CA3122475A1 (es) |
CL (3) | CL2021001712A1 (es) |
CO (1) | CO2021008091A2 (es) |
EC (1) | ECSP21046159A (es) |
GB (1) | GB201821269D0 (es) |
IL (1) | IL284342A (es) |
MX (1) | MX2021007740A (es) |
PE (1) | PE20211732A1 (es) |
PH (1) | PH12021551187A1 (es) |
SG (1) | SG11202106511UA (es) |
TW (1) | TW202039848A (es) |
WO (1) | WO2020138509A1 (es) |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
JP3398378B2 (ja) | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
JP2924179B2 (ja) | 1993-02-19 | 1999-07-26 | 日本新薬株式会社 | グリセロール誘導体,デバイス及び医薬組成物 |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
EP1811024A1 (en) | 2004-10-05 | 2007-07-25 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna and medicinal composition |
CA2609032A1 (en) | 2005-05-30 | 2006-12-07 | Nippon Shinyaku Co., Ltd. | Method for producing a nucleic-acid-containing complex preparation |
SI2024499T1 (en) | 2006-05-10 | 2018-04-30 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
CN101121933A (zh) * | 2006-08-11 | 2008-02-13 | 中国科学院上海生命科学研究院 | 用于激酶基因过表达相关疾病的siRNA |
JP5347510B2 (ja) | 2007-02-05 | 2013-11-20 | 日本新薬株式会社 | ポリエチレングリコール誘導体 |
US20090099066A1 (en) | 2007-06-29 | 2009-04-16 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
CA2884340C (en) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Method of synthesis of morpholino oligomers |
US8106022B2 (en) | 2007-12-04 | 2012-01-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
US8906877B2 (en) * | 2009-02-20 | 2014-12-09 | GenRemedy, LLC | Method for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis |
KR20190090049A (ko) * | 2009-06-12 | 2019-07-31 | 악셀레론 파마 인코포레이티드 | 절두된 ActRIIB-FC 융합 단백질 |
TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
WO2012138223A2 (en) * | 2011-04-05 | 2012-10-11 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Compounds and methods for altering activin receptor-like kinase signalling |
JP6478632B2 (ja) | 2011-05-05 | 2019-03-06 | サレプタ セラピューティクス, インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
IN2014CN03463A (es) | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
SI2992009T1 (sl) | 2013-05-01 | 2020-10-30 | Ionis Pharmaceuticals, Inc. | Sestavki in postopki za moduliranje izražanja apolipoproteina (A) |
AU2014287002A1 (en) | 2013-07-11 | 2016-02-11 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
EP3079723B1 (en) | 2013-12-12 | 2020-05-27 | Life Technologies Corporation | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
JP6482475B2 (ja) | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
GB201421379D0 (en) * | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
BR112017024929A2 (pt) | 2015-05-19 | 2018-07-31 | Sarepta Therapeutics, Inc. | conjugados de oligonucleotídeo-peptídeo |
JPWO2017010575A1 (ja) | 2015-07-16 | 2018-04-26 | 協和発酵キリン株式会社 | β2GPI遺伝子発現抑制核酸複合体 |
SG11201802138TA (en) * | 2015-09-15 | 2018-04-27 | Nippon Shinyaku Co Ltd | Antisense nucleic acid |
WO2017047741A1 (ja) * | 2015-09-16 | 2017-03-23 | 日本新薬株式会社 | 筋萎縮症治療用アンチセンス核酸 |
JP2018530560A (ja) * | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
CN117298290A (zh) | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
CA3046793A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
MX2019006879A (es) | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
US11603532B2 (en) * | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
-
2018
- 2018-12-28 GB GBGB1821269.6A patent/GB201821269D0/en not_active Ceased
-
2019
- 2019-12-26 EP EP19848821.5A patent/EP3902916A1/en active Pending
- 2019-12-26 BR BR112021012488-8A patent/BR112021012488A2/pt unknown
- 2019-12-26 SG SG11202106511UA patent/SG11202106511UA/en unknown
- 2019-12-26 WO PCT/JP2019/051651 patent/WO2020138509A1/en active Application Filing
- 2019-12-26 CN CN201980085589.0A patent/CN113272429A/zh active Pending
- 2019-12-26 MX MX2021007740A patent/MX2021007740A/es unknown
- 2019-12-26 TW TW108148268A patent/TW202039848A/zh unknown
- 2019-12-26 KR KR1020217020055A patent/KR20210110593A/ko not_active Application Discontinuation
- 2019-12-26 PE PE2021001062A patent/PE20211732A1/es unknown
- 2019-12-26 JP JP2021561143A patent/JP2022516207A/ja active Pending
- 2019-12-26 AU AU2019415399A patent/AU2019415399A1/en active Pending
- 2019-12-26 CA CA3122475A patent/CA3122475A1/en active Pending
- 2019-12-26 US US17/417,436 patent/US20220119818A1/en active Pending
-
2021
- 2021-05-24 PH PH12021551187A patent/PH12021551187A1/en unknown
- 2021-06-21 CO CONC2021/0008091A patent/CO2021008091A2/es unknown
- 2021-06-23 IL IL284342A patent/IL284342A/en unknown
- 2021-06-25 CL CL2021001712A patent/CL2021001712A1/es unknown
- 2021-06-25 EC ECSENADI202146159A patent/ECSP21046159A/es unknown
-
2023
- 2023-06-27 CL CL2023001902A patent/CL2023001902A1/es unknown
- 2023-06-27 CL CL2023001901A patent/CL2023001901A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021008091A2 (es) | 2021-06-30 |
SG11202106511UA (en) | 2021-07-29 |
CL2021001712A1 (es) | 2022-01-07 |
KR20210110593A (ko) | 2021-09-08 |
PE20211732A1 (es) | 2021-09-06 |
WO2020138509A1 (en) | 2020-07-02 |
CA3122475A1 (en) | 2020-07-02 |
JP2022516207A (ja) | 2022-02-24 |
CL2023001902A1 (es) | 2023-12-15 |
PH12021551187A1 (en) | 2022-01-03 |
MX2021007740A (es) | 2021-08-05 |
CN113272429A (zh) | 2021-08-17 |
ECSP21046159A (es) | 2021-07-30 |
IL284342A (en) | 2021-08-31 |
US20220119818A1 (en) | 2022-04-21 |
BR112021012488A2 (pt) | 2021-09-08 |
TW202039848A (zh) | 2020-11-01 |
GB201821269D0 (en) | 2019-02-13 |
AU2019415399A1 (en) | 2021-06-03 |
EP3902916A1 (en) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111882A1 (es) | Inhibidores de kras g12c y métodos para su uso | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
CL2018003322A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128) | |
JOP20200122B1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
MX2020003666A (es) | Compuestos y composiciones para el tratamiento de trastornos hematologicos. | |
CY1119817T1 (el) | Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης | |
CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
MX2022001655A (es) | Dispersiones solidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc). | |
CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
CY1122018T1 (el) | Παραγωγα 6-μορφολινυλ-2-πυραζολυλ-9η-πουρινης και η χρηση αυτων ως αναστολεις ρι3κ | |
BR112022005674A2 (pt) | Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo | |
AR117297A1 (es) | Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos | |
CL2020002352A1 (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
CY1124911T1 (el) | Συνθεσεις πεπτιδιων και μεθοδοι χρησης | |
MX2015012012A (es) | Peptidos de kntc2 y vacunas que los contienen. | |
CO2022003321A2 (es) | Moduladores de sting (estimulador de genes de interferón) | |
CL2023001901A1 (es) | Inhibidor de señal de miostatina | |
MX2019008105A (es) | Virus. | |
CL2022000193A1 (es) | Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422) | |
PE20181012A1 (es) | Composicion oral de liberacion retardada dual novedosa dexlansoprozol | |
TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2015007015A (es) | Peptidos sema5b y vacunas que contienen los mismos. | |
AR105666A1 (es) | Inhibidores de ezh2 |